39 results on '"Noronha, Glenn"'
Search Results
2. SUPRACHOROIDAL INJECTION OF TRIAMCINOLONE ACETONIDE, CLS-TA, FOR MACULAR EDEMA DUE TO NONINFECTIOUS UVEITIS: A Randomized, Phase 2 Study (DOGWOOD)
3. Phosphoinositide 3-Kinase γ/δ Inhibition Limits Infarct Size after Myocardial Ischemia/Reperfusion Injury
4. Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
5. Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors
6. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits
7. Phosphoinositide 3-kinase [gamma]/[delta] inhibition limits infarct size after myocardial ischemia/reperfusion injury
8. Suprachoroidal Triamcinolone Acetonide for Diabetic Macular Edema: The HULK Trial
9. Preparation of a new class of cleavable surfactants based on the silicon-carbon bond
10. Suprachoroidally injected pharmacological agents for the treatment of chorio‐retinal diseases: a targeted approach.
11. Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema.
12. The design and preliminary structure–activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes
13. Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine—a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays
14. Discovery and preliminary structure–activity relationship studies of novel benzotriazine based compounds as Src inhibitors
15. Serotonin 5-HT1A Receptor Agonists in Oxidative Stress and Retinal Disease.
16. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema.
17. Primary Cell Experiments with TG101348, a JAK2-Selective Inhibitor, in the Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515L/K, and JAK2 Exon 12 Mutations.
18. TG101348: A Dual-Acting JAK2/FLT3 Small Molecule Kinase Inhibitor for the Treatment of AML.
19. Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.
20. JAK2 Inhibitors for the Treatment of Myeloprolifertive Disorders.
21. Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.
22. TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2V617F or MPLW515K/L Mutations.
23. In Vitro and In Vivo Inhibition of the T315I Mutant BCR/ABL Kinase.
24. Discovery of [7-(2,6-Dichlorophenyl)-5-methylbenzo[1,2,4]triazin-3-yl]- [4-(2-pyrrolidin-1-ylethoxy)phenyl]amine - A Potent, Orally Active Src Kinase Inhibitor with Antitumor Activity in Preclinical Assays.
25. ChemInform Abstract: Preparation of a New Class of Cleavable Surfactants Based on the Silicon-Carbon Bond.
26. Heterogenized polymetallic catalysts: Part III. Catalytic air oxidation of alcohols by Pd(II) complexed to a polyphenylene polymer containing β-di- and tri-ketone surface ligands
27. Heterogenized polymetallic catalysts Part II. Oxidation of 3,5-di-t-butylphenol by Cu(II), Fe(III) and Pd(II) complexed to a polyphenylene polymer containing ß-di- and triketone surface ligands; an improved catalyst system
28. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial.
29. Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates.
30. Reply.
31. Choroidal Changes After Suprachoroidal Injection of Triamcinolone Acetonide in Eyes With Macular Edema Secondary to Retinal Vein Occlusion.
32. Suprachoroidal Corticosteroid Administration: A Novel Route for Local Treatment of Noninfectious Uveitis.
33. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
34. Development of novel benzotriazines for drug discovery.
35. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.
36. Inhibitors of ABL and the ABL-T315I mutation.
37. Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.
38. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine).
39. Synthesis of Peptide Isocyanates and Isothiocyanates.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.